Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MetaVia Inc.NRBO · Entity 7947 | CEO and President | November 03, 2021 | November 04, 2021 |
| Opus Genetics, Inc.RNN · Entity 5892 | Director | June 06, 2019 | June 07, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MetaVia Inc.
Report date November 03, 2021 · Filed November 04, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Nonstatutory Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.04 · Expires 2031-11-03 | Direct | 616,666 |
Reported balance
After 2021-11-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-03 · Grant · Acquired 616,666 · Balance 616,666 F1: 266,666 shares subject to the option vest on the first anniversary of the vesting commencement date, November 3, 2021, and the remaining 350,000 shares subject to the option vest on the second anniversary of the vesting commencement date, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: 266,666 shares subject to the option vest on the first anniversary of the vesting commencement date, November 3, 2021, and the remaining 350,000 shares subject to the option vest on the second anniversary of the vesting commencement date, subject to the Reporting Person's continuous service.
Opus Genetics, Inc.
Report date June 06, 2019 · Filed June 07, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.23 · Expires 2029-06-06 | Direct | 3,537 |
Reported balance
After 2019-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-06 · Grant · Acquired 3,537 · Balance 3,537 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 03, 2021 Filed Nov 4, 2021 16:57 UTC | MetaVia Inc. NRBO · Entity 7947 | GrantNonstatutory Stock Option (right to buy) · Derivative | 616,666 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0001596771-21-000068 · primary_doc.xml · derivative · entry 1 Price Ben Gil · CIK 0001417915 · CEO and President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,666 Underlying: Common Stock · 616,666 shares Expires 2031-11-03 F1 · derivative.exercise_date: 266,666 shares subject to the option vest on the first anniversary of the vesting commencement date, November 3, 2021, and the remaining 350,000 shares subject to the option vest on the second anniversary of the vesting commencement date, subject to the Reporting Person's continuous service. Read SEC document |
| June 06, 2019 Filed Jun 7, 2019 16:12 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 3,537 | $0.00 Strike: $5.23 | $0.00 |
DisclosureSEC source: 0001140361-19-010669 · form4.xml · derivative · entry 1 Price Ben Gil · CIK 0001417915 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,537 Underlying: Common Stock · 3,537 shares Expires 2029-06-06 Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 07:56 UTC | Opus Genetics, Inc. RNN · Entity 5892 | PurchaseCommon Stock | 15,000 | $0.61 | $9,141.00 |
DisclosureSEC source: 0001140361-19-002082 · form4.xml · nonDerivative · entry 1 Price Ben Gil · CIK 0001417915 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · price: The price of $0.6094 per share represents a weighted average of purchase prices ranging from $0.6016 to $0.6100 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or any security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price. Read SEC document |
| November 29, 2018 Filed Dec 3, 2018 17:10 UTC | Opus Genetics, Inc. RNN · Entity 5892 | GrantStock Option (right to buy) · Derivative | 112,878 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001140361-18-044426 · form4.xml · derivative · entry 1 Price Ben Gil · CIK 0001417915 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,878 Underlying: Common Stock · 112,878 shares Expires 2028-11-29 F1 · derivative.exercise_date: Options will vest and become exercisable based on the following schedule: 37,626 on November 29, 2019, 37,626 on November 29, 2020, and 37,626 on November 29, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.